- Home
- VRNS vs ERAS Comparison
VRNS vs ERAS Comparison
Compare VRNS & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRNS | ERAS |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | 103 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.0B |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VRNS | ERAS |
|---|---|---|
| Price | $32.36 | $13.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 12 |
| Target Price | ★ $42.75 | $14.25 |
| AVG Volume (30 Days) | 1.7M | ★ 4.7M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $270,288,000.00 | N/A |
| Revenue This Year | $18.87 | N/A |
| Revenue Next Year | $17.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 24.35 | N/A |
| 52 Week Low | $19.70 | $1.24 |
| 52 Week High | $63.90 | $24.28 |
Technical Indicators
Market Signals| Indicator | VRNS | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 58.41 | 53.19 |
| Support Level | $31.14 | $2.11 |
| Resistance Level | $34.07 | $15.03 |
| Average True Range (ATR) | 1.56 | 1.05 |
| MACD | -0.14 | 0.30 |
| Stochastic Oscillator | 46.96 | 59.83 |
Price Performance
Historical ComparisonAbout VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.